OP0027 LONG-TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN SEVERE AND TREATMENT REFRACTORY AUTOIMMUNE DISEASE
J. Taubmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Georg Schett(Karolinska University Hospital), Dimitrios Mougiakakos(Otto-von-Guericke-Universität Magdeburg), Christina Bergmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), L. Bucci(Friedrich-Alexander-Universität Erlangen-Nürnberg), Melanie Hagen(James Madison University), Fabian Müller(Friedrich-Alexander-Universität Erlangen-Nürnberg), Carlo Tur(Agostino Gemelli University Polyclinic), Michael Aigner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Gerhard Krönke(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ricardo Grieshaber‐Bouyer(Heidelberg University), Anne‐Sophie Korganow(Inserm), Aline Bözec(Center for Rheumatology), Simon Völkl(Universitätsklinikum Erlangen), Andréas Mackensen(University Medical Center Freiburg), Filippo Fagni(Universitätsklinikum Erlangen), Dominique Farge(Hôpital Saint-Louis)
Cited by 8
Related Papers
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
|Journal of Clinical Investigation|2012|708
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538
Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease
|Circulation|2004|507
Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
|Journal of the American College of Cardiology|2012|463